Growth Differentiation Factor 15 Provides Prognostic Information Superior to Established Cardiovascular and Inflammatory Biomarkers in Unselected Patients Hospitalized With COVID-19
Authors:
- Peder L. MyhrePeder L. Myhre
- Christian PrebensenCPChristian Prebensen
- Heidi StrandHSHeidi Strand
- Ragnhild RøyslandRRRagnhild Røysland
- Christine M. JonassenCJChristine M. Jonassen
- Anbjørg RangbergARAnbjørg Rangberg
- Vibecke SørensenVSVibecke Sørensen
- Signe SøvikSSSigne Søvik
- Helge RøsjøHRHelge Røsjø
- My SvenssonMSMy Svensson
- Jan Erik BerdalJBJan Erik Berdal
- Torbjørn OmlandTOTorbjørn Omland
- 1 December 2020
- journal article
- research article
- Published by Wolters Kluwer Health in Circulation
- Vol. 142 (22) , 2128-2137
Abstract
Background: Growth differentiation factor 15 (GDF-15) is a strong prognostic marker in sepsis and cardiovascular disease (CVD). The prognostic value of GDF-15 in coronavirus disease 2019 (COVID-19) is unknown. Methods: Consecutive, hospitalized patients with laboratory-confirmed infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and symptoms of COVID-19 were enrolled in the prospective, observational COVID Mechanisms Study. Biobank samples were collected at baseline, day 3 and day 9. The primary end point was admission to the intensive care unit or death during hospitalization, and the prognostic performance of baseline and serial GDF-15 concentrations were compared with that of established infectious disease and cardiovascular biomarkers. Results: Of the 123 patients enrolled, 35 (28%) reached the primary end point; these patients were older, more often had diabetes, and had lower oxygen saturations and higher National Early Warning Scores on baseline. Baseline GDF-15 concentrations were elevated (>95th percentile in age-stratified healthy individuals) in 97 (79%), and higher concentrations were associated with detectable SARS-CoV-2 viremia and hypoxemia (both P P P P <0.001). Conclusions: GDF-15 is elevated in the majority of patients hospitalized with COVID-19, and higher concentrations are associated with SARS-CoV-2 viremia, hypoxemia, and worse outcome. The prognostic value of GDF-15 was additional and superior to established cardiovascular and inflammatory biomarkers. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT04314232.Keywords
This publication has 21 references indexed in Scilit:
- Growth Differentiation Factor-15 Deficiency Augments Inflammatory Response and Exacerbates Septic Heart and Renal Injury Induced by LipopolysaccharideScientific Reports, 2017
- Growth Differentiation Factor 15 as a Biomarker in Cardiovascular DiseaseClinical Chemistry, 2017
- GDF-15 Is Associated with Cancer Incidence in Patients with Type 2 DiabetesClinical Chemistry, 2016
- GDF-15 Is Elevated in Children with Mitochondrial Diseases and Is Induced by Mitochondrial DysfunctionPLOS ONE, 2016
- The multiple facets of the TGF-β family cytokine growth/differentiation factor-15/macrophage inhibitory cytokine-1Cytokine & Growth Factor Reviews, 2013
- Change in Growth Differentiation Factor 15 Concentrations over Time Independently Predicts Mortality in Community-Dwelling Elderly IndividualsClinical Chemistry, 2013
- Association of Growth Differentiation Factor-15 with Coronary Atherosclerosis and Mortality in a Young, Multiethnic Population: Observations from the Dallas Heart StudyClinical Chemistry, 2012
- GDF-15 is abundantly expressed in plexiform lesions in patients with pulmonary arterial hypertension and affects proliferation and apoptosis of pulmonary endothelial cellsRespiratory Research, 2011
- Relation of Growth-Differentiation Factor 15 to Left Ventricular Remodeling in ST-Segment Elevation Myocardial InfarctionThe American Journal of Cardiology, 2011
- Growth differentiation factor-15/macrophage inhibitory cytokine-1 induction after kidney and lung injury.2005